
According to data from Benzinga Pro, during Q1, Catalyst Biosciences's (NASDAQ:CBIO) reported sales totaled $794.00 thousand. Despite a 28.5% increase in earnings, the company posted a loss of $14.54 million. Catalyst Biosciences collected $2.44 million in revenue during Q4, but reported earnings showed a $20.33 million loss.